'Accelerating research and discovery' – Human Platelet Lysate in North America 'Accelerating research and discovery'. The mission of the team at Captivate Bio perfectly fits our mission: Providing one solution for all development stages – Human Platelet Lysate. From the beginning, we saw strong synergies between our companies.
PL BioScience raises € 3.7 mln from Born2Grow, Brightlands Venture Partners, TechVision Fund I and more The capital will be used to expand R&D, increase sales capacity and scale up in-house production PL BioScience produces a human-based nutrient medium for growing cells, as replacement for animal-derived
World Earth Day 2021: Environmental Impact of HPL vs. FBS What do HPL and FBS have to do with the Earth Day 2021? The Earth Day raises awareness and educates people about a more sustainable living. For us, this means we educate about a more sustainable cell
Animal experiments are one of the most discussed topics in research and in our society. We neither want to condemn animal experiments nor do we want to trivialize this topic. What we want is to raise awareness and open a fact-based discussion about it. Animal experiments are
A new publication from Kouroupis et al. published in CYTOTHERAPY in July 2020 found out that infrapatellar fat pad (IFP)-mesenchymal stem cells (MSCs) manufactured with human Platelet Lysate (hPL) show enhanced immunomodulatory properties. Findings have potential for a minimally invasive cell therapy for joint disease The authors even
It is a pleasure for us to announce that BORN2GROW GmbH & Co. KG, a subsidiary of Zukunftsfonds Heilbronn (ZFHN), invests in our company and technology. Since almost 20 years the ZFHN successfully consults and accompanies start-up technologies and companies. BORN2GROW is the second investor in
Read in the press article from the "Aachener Zeitung" why human Platelet Lysate is still unusual but morally inoffensive PL BioScience produces human Platelet Lysate (hPL) as a cell culture supplement. This is still unusual because using the controversial Fetal Bovine Serum (FBS) for cell culture
The study performed with human Platelet Lysate (hPL) at the University of Miami showed an enhanced performance of manufactured IFP - MSCs under regulatory compliant conditions. The aim of the study was to proof the hypothesis: IFP-MSCs manufactured under these conditions do not need "ex-vivo priming
Meet PL BioScience at the annual GSCN Conference From 23 to 25 September the annual Conference of the German Stem Cell Network (GSCN) will take place. We will be part of it in the virtual exhibition. Special times require special actions Because of the corona safety requirements and
Human Platelet Lysate should seriously considered as the new standard "hPL has favorable properties in terms of ethics and scientific practice and should seriously be considered as a new standard cell culture medium substitute". HPL can replace FCS as a protein source This is only one of the
Despite the challenging times, we would like to wish you and your families a happy Easter. We hope that you and your loved ones are healthy and safe. We certainly continue to support your business with our cell culture supplements. We adapted our processes to provide
Fatal disadvantages of FBS shown The essay by Toni Lindl and Gerhard Gstraunthaler demonstrates the fatal disadvantages of Fetal Bovine Serum (FBS). The article published in the German scientific magazine 'Laborjournal' proposes a contemporary cell culture solution: Human Platelet Lysate (hPL). High reproducibility of trial results achieved
PL BioScience team participates in the AC² Innovation Award ceremony The PL BioScience team participated in the AC² Innovation Award ceremony in the historic city hall of Aachen. During the event, the winner of the award has been announced. PL BioScience was nominated as one of 5
PL BioScience is mentioned in the local newspaper ‘Aachener Zeitung’ one more time. Prior to the award ceremony on 6 June 2019, PL BioScience is presented in the recent press article as one of the five finalists. Our whole team is delighted about the appreciation and innovative strength
PL BioScience ensures its Good Manufacturing Practice throughout all process steps. We strive to offer high-quality services - from manufacture to the advise of our customers. For that reason, we established a holistic quality management system underlining our own commitment to quality. Recently, our Good Manufacturing
PL BioScience in 'Journal of the Chamber of Industry and Commerce Aachen' (Wirtschaftliche Nachrichten der Industrie- und Handelskammer Aachen) As one of the five finalists of the AC² Innovation Award 2019, we were able to present our patent-protected technologies to the Journal. The recent report pictures our novel cell
PL BioScience's technology in the local newspaper 'Aachener Zeitung'. Our platelet-based technology is one out of five 'technologies of the future' nominated for the AC² Innovation Award 2019 which honours one local laureate with unique innovative strength. 'Aachener Zeitung' has just presented the five finalists which have the opportunity
With our novel 2D and 3D cell culture media, we made it to the final round of the AC² Innovation Award 2019 for the Aachen region. Our technology based on human blood platelets is one out of five 'technologies of the future' nominated for the award.
The five finalists of the AC² Innovation Award 2019 for the Aachen region have just presented their technologies to the jury. Beforehand, the AGIT (Aachen Society for Innovation and Technology Transfer), the chambers and universities selected numerous local companies with innovative strength. We are very pleased to
"We demonstrate that human platelet lysate (hPL) can replace hS in macrophage cultivation [
